Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Bucknelly21on Sep 19, 2022 3:12pm
126 Views
Post# 34971912

RE:RE:RE:I give up

RE:RE:RE:I give upI have a hard time to fathom that they really think the stradegy in addressing the market is how they have been. Its why everyone is angry and saying incapables. At some point they will need to look in the mirror. They operate as if they have a large following waiting for updates, they have a small following of people who have been generally right for the last few years and have nothing to show for it. They hired a somewhat strange ir person although she is nice. She seems to be an underling of phillipe giving no real answers when you ask a question. Also she says how fortunate she is to work with this amazingly talented team. Lets be real for a minute, the only person holding up to their end of the deal is marsolis, everyone else has massively underachieved. Paul has not justified his 2 mil salary at all. He talks nice unfortunately his follow though on the plans he spoke to wino about has been poor. I remember a while back how in a call with an employee they said we are not liars like cydy well from where im sitting looks like a few of those promises were lies including when pual told rusty they would bot dilute. So not only have they lost credibility with the market, now the most loyal of shareholders are reach their breaking point. At this point im over bashing, they know whether they admit it or not that they have severely damaged their reputation all over by their lack of engagement and lack of adapting to the markets 
<< Previous
Bullboard Posts
Next >>